minocycline (Dynacin, Minocin) (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
STORAGE: Minocycline immediate-release tablets and capsules should be stored between 20 C-25 C (68 F-77 F). Minocycline extended-release tablets should be stored between 15 C -30 C (59 F-86 F).
PRESCRIBED FOR: Minocycline immediate-release tablets and capsules are used for infections caused by Mycoplasma pneumonia, Chlamydia trachomatis, Borrelia recurrentis, Yersinia pestis, Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, respiratory tract infections caused by Haemophilus influenza and Streptococcus pneumoniae, and respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline extended-release tablets are used to treat inflammatory lesions of non-nodular moderate-to-severe acne vulgaris. Minocycline is used for treating Rocky Mountain spotted fever, typhus and other infections caused by the typhus group of bacteria, Q fever, rickettsialpox and tick fevers caused by rickettsiae.
Adults (immediate-release tablets and capsules): The recommended dose for minocycline is: 200 mg initially, followed by 100 mg every 12 hours. If more frequent doses are preferred, then two or four 50 mg capsules initially, followed by 500 mg 4 times a day.
Children 8 years of age and older (immediate-release tablets and capsules): The recommended dose of minocycline is: 4 mg/kg initially, followed by 2 mg/kg every 12 hours, not to exceed the usual adult dose.
Adults and children 12 years of age and older (extended-release tablets): The recommended dose for minocycline is: Approximately 1 mg/kg by mouth once daily for up to 12 weeks for the treatment of inflammatory lesions of non-nodular acne vulgaris.
Medically Reviewed by a Doctor on 10/3/2014
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index